US Sends First Humanitarian Aid Flight to Cuba Under $100M Assistance Plan 
Maduro, U.S. Prosecutors Propose June 2027 Trial Date in Drug Trafficking Case 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
US Military Completes 11th Straight Day of Iran Strikes Amid Strait of Hormuz Security Concerns 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Trump Says Talks With UK PM Andy Burnham Went Well, Signals Meeting Soon 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Trump Set to Unveil New Tariffs on Dozens of Countries as Global 10% Duty Nears Expiration 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
US-Iran War Enters 11th Day as Costs Climb to $37.5 Billion, Trump Warns of More Strikes 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
FCC Moves to Ban Imports of Foreign Military-Grade Drones Over Security Risks 
U.S. Plans Closer Coordination With Erik Prince’s Haiti Security Firm 
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) is facing leadership uncertainty after acting director Jeffery Taubenberger stepped down during ongoing Ebola and hantavirus outbreak concerns. The departure was revealed Thursday during a Senate hearing on the National Institutes of Health (NIH) 2027 budget, sparking criticism from Democratic lawmakers over the agency’s preparedness for emerging infectious diseases.
Taubenberger assumed the acting director role in April 2025 after the Trump administration removed former NIAID leadership. Senator Tammy Baldwin announced his resignation at the hearing, while Senator Patty Murray also referenced the sudden exit. NIH Director Jay Bhattacharya did not deny the reports and said the agency is shifting priorities away from civilian biodefense and pandemic preparedness toward direct infectious disease response, allergy research, and immunology.
The leadership change comes as global health officials monitor an Ebola outbreak in the Democratic Republic of Congo and potential hantavirus exposure linked to a luxury cruise ship outbreak in the Atlantic Ocean. Although no confirmed U.S. cases of Andes hantavirus have been reported, 41 individuals, including 18 people quarantined in Nebraska, remain under observation.
Former NIAID director Jeanne Marrazzo criticized the current situation, warning that the institute appears disconnected from researchers and pharmaceutical companies working on Ebola treatments. Under former director Anthony Fauci, NIAID played a major role in managing both the COVID-19 pandemic and the 2014-2016 Ebola crisis in West Africa.
The latest departures add to growing concerns about instability within the NIH, where more than half of its 27 institutes are currently overseen by acting directors. NIAID, the NIH’s second-largest institute with a budget exceeding $6.5 billion, remains central to U.S. infectious disease research and public health response efforts.
